Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma — Stella

Home/Metastatic Colorectal Carcinoma (mCRC)/Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

View on ClinicalTrials.gov

Recruiting

Back to Metastatic Colorectal Carcinoma (mCRC) trials

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Clinical Trials Nurse Navigator, Scottsdale, Arizona

Key details

Phase

Early testing / Safety & dosing

Sponsor

HonorHealth Research Institute

Collaborators

Iterion Therapeutics

Enrollment target

~126 participants

Started

February 2026

Primary completion

January 2029

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.